
Annual report 2025
added 11-25-2025
Becton, Dickinson and Company EBITDA 2011-2025 | BDX
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Becton, Dickinson and Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.04 B | 4.68 B | 4.4 B | 4.51 B | 4.48 B | 3.03 B | 4.49 B | 4.22 B | 2.92 B | 3.27 B | 2.39 B | 2.17 B | 1.8 B | 2.07 B | 2.27 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.04 B | 1.8 B | 3.45 B |
Quarterly EBITDA Becton, Dickinson and Company
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.28 B | 942 M | 1.06 B | 964 M | 1.1 B | 1 B | 916 M | 994 M | 1.15 B | - | 894 M | 916 M | 1.24 B | - | 1.74 B | 784 M | 1.8 B | 2.83 B | 1.42 B | 1.8 B | 1.03 B | 3.35 B | 1.75 B | 1.03 B | 1.45 B | 2.34 B | 1.36 B | 1.45 B | 526 M | 1.84 B | 300 M | 521 M | 1.07 B | 2.18 B | 1.08 B | 1.07 B | 641 M | 1.36 B | 414 M | 641 M | 488 M | 1.62 B | 717 M | 488 M | 520 M | 1.58 B | 670 M | 520 M | 521 M | 1.55 B | 710 M | 521 M | 470 M | 888 M | 202 M | 494 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.35 B | 202 M | 1.11 B |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical instruments industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Baxter International
BAX
|
1.01 B | $ 19.11 | 0.95 % | $ 9.75 B | ||
|
Luminex Corporation
LMNX
|
72.9 M | - | - | $ 1.75 B | ||
|
Akers Biosciences, Inc.
AKER
|
-12.3 M | - | -9.52 % | $ 20.6 M | ||
|
Ekso Bionics Holdings
EKSO
|
-8.85 M | $ 5.47 | 3.01 % | $ 110 M | ||
|
Antares Pharma, Inc.
ATRS
|
16.2 M | - | - | $ 955 M | ||
|
Cantel Medical Corp.
CMD
|
123 M | - | -1.18 % | $ 3.4 B | ||
|
CRH Medical Corporation
CRHM
|
33.9 M | - | - | $ 282 M | ||
|
Hill-Rom Holdings, Inc.
HRC
|
518 M | - | -0.05 % | $ 10.3 B | ||
|
Harvard Bioscience
HBIO
|
3.37 M | $ 0.73 | 0.64 % | $ 31 M | ||
|
Varian Medical Systems, Inc.
VAR
|
60 M | - | -0.02 % | $ 16.3 B | ||
|
iRhythm Technologies
IRTC
|
-94.8 M | $ 175.8 | -1.49 % | $ 5.48 B | ||
|
ICU Medical
ICUI
|
262 M | $ 146.98 | -0.35 % | $ 3.58 B | ||
|
Alcon
ALC
|
580 M | $ 80.17 | 0.06 % | $ 40.4 B | ||
|
Repro Med Systems
KRMD
|
-9.4 M | $ 6.48 | -0.61 % | $ 295 M | ||
|
AtriCure
ATRC
|
-28.8 M | $ 40.55 | 0.02 % | $ 1.9 B | ||
|
Atrion Corporation
ATRI
|
37.7 K | - | - | $ 810 M | ||
|
LeMaitre Vascular
LMAT
|
61.9 M | $ 84.34 | 0.44 % | $ 1.89 B | ||
|
electroCore
ECOR
|
-18.3 M | $ 4.86 | 1.25 % | $ 26.8 K | ||
|
AngioDynamics
ANGO
|
-14.2 M | $ 13.16 | - | $ 538 M | ||
|
Merit Medical Systems
MMSI
|
258 M | $ 87.39 | -0.27 % | $ 5.09 B | ||
|
The Cooper Companies
COO
|
1.06 B | $ 82.57 | -0.37 % | $ 16.4 B | ||
|
Glaukos Corporation
GKOS
|
-95 M | $ 116.64 | 0.4 % | $ 5.65 B | ||
|
Masimo Corporation
MASI
|
-164 M | $ 133.28 | -0.44 % | $ 7.1 B | ||
|
Haemonetics Corporation
HAE
|
337 M | $ 80.01 | -0.44 % | $ 4.03 B | ||
|
InfuSystem Holdings
INFU
|
15 M | $ 9.11 | 0.77 % | $ 188 M | ||
|
Isoray
ISR
|
-88.6 M | - | 0.03 % | $ 108 M | ||
|
Intuitive Surgical
ISRG
|
2.79 B | $ 577.15 | -0.03 % | $ 205 B | ||
|
OraSure Technologies
OSUR
|
-17.4 M | $ 2.43 | 2.53 % | $ 181 M | ||
|
Microbot Medical
MBOT
|
-9.75 M | $ 2.18 | - | $ 22.2 M | ||
|
ResMed
RMD
|
1.16 B | $ 244.44 | -0.07 % | $ 35.7 B | ||
|
Milestone Scientific
MLSS
|
-6.72 M | $ 0.29 | -0.48 % | $ 23.1 M | ||
|
Nephros
NEPH
|
-1.38 M | $ 5.23 | 12.23 % | $ 54.3 M | ||
|
NeuroMetrix
NURO
|
-8.69 M | - | 5.05 % | $ 9.02 M | ||
|
Envista Holdings Corporation
NVST
|
-915 M | $ 22.0 | 0.59 % | $ 3.79 B | ||
|
STAAR Surgical Company
STAA
|
-5.72 M | $ 23.63 | -1.25 % | $ 1.16 B | ||
|
STERIS plc
STE
|
1.34 B | $ 255.68 | 0.11 % | $ 25.2 B | ||
|
Stereotaxis
STXS
|
-21.2 M | $ 2.43 | -0.82 % | $ 196 M | ||
|
Pro-Dex
PDEX
|
11.9 M | $ 40.4 | -2.38 % | $ 133 M | ||
|
Pulse Biosciences
PLSE
|
-43 M | $ 14.86 | 1.92 % | $ 714 M | ||
|
Predictive Oncology
POAI
|
-10.8 M | - | - | $ 32.4 M | ||
|
Utah Medical Products
UTMD
|
17.4 M | $ 56.29 | -1.14 % | $ 204 M | ||
|
Repligen Corporation
RGEN
|
116 M | $ 165.66 | -0.42 % | $ 9.23 M | ||
|
DENTSPLY SIRONA
XRAY
|
-530 M | $ 11.22 | 1.26 % | $ 2.28 B | ||
|
BioLife Solutions
BLFS
|
-1.97 M | $ 25.41 | -0.2 % | $ 1.17 B | ||
|
Retractable Technologies
RVP
|
-13.5 M | $ 0.82 | 0.01 % | $ 24.5 M | ||
|
Teleflex Incorporated
TFX
|
426 M | $ 122.33 | 0.03 % | $ 5.73 B | ||
|
West Pharmaceutical Services
WST
|
725 M | $ 276.66 | -0.3 % | $ 20.2 B |